4.3 Article

Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers

Journal

JOURNAL OF THORACIC DISEASE
Volume 12, Issue 5, Pages 1952-+

Publisher

AME PUBLISHING COMPANY
DOI: 10.21037/jtd-20-1

Keywords

Non-small cell lung cancer; multiple synchronous lung cancers; genomic heterogeneity; gene sequencing

Funding

  1. MD Anderson Lung Cancer Moon Shot Program
  2. Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award [RP160668]
  3. MD Anderson Physician Scientist Program
  4. University of Texas (UT) Systems Stars Award [PS100149]
  5. Welch Foundation Robert A. Welch Distinguished University Chair Award [G-0040]
  6. Department of Defense PROSPECT grant [W81XWH-07-1-0306]
  7. UT Lung Specialized Programs of Research Excellence Grant [P50CA70907]
  8. MD Anderson Cancer Center Support Grant [CA016672]
  9. T.J. Martell Foundation

Ask authors/readers for more resources

Background: Multiple synchronous lung tumors (MSLT), particularly within a single lobe, represent a diagnostic and treatment challenge. While histologic assessment was once the only method to possibly distinguish multiple primary lung cancers, there is a growing interest in identifying unique genomic features or mutations to best characterize these processes. Methods: In order to differentiate multiple primary lung malignancies from intrapulmonary metastases in patients with MSLT, we performed whole exome sequencing (WES) on 10 tumor samples from 4 patients with MSLT. Results: Shared mutations between tumors from the same patient varied from 0-91%. Patient 3 shared no common mutations; however, in Patients 2 and 4, identical mutations were identified among all tumors from each patient, suggesting that the three tumors identified in Patient 3 represent separate primary lung cancers, while those of Patients 1, 2 and 4 signify hematogenous and lymphatic spread. Conclusions: A high proportion of shared mutations between different lung tumors is likely indicative of intrapulmonary metastatic disease, while tumors with distinct genomic profiles likely represent multiple primary malignancies driven by distinct molecular events. Application of genomic profiling in the clinical setting may prove to be important to precise management of patients with MSLT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available